Astria Therapeutics Inc (NAS:ATXS)
$ 9.17 -0.11 (-1.19%) Market Cap: 503.55 Mil Enterprise Value: 235.18 Mil PE Ratio: 0 PB Ratio: 1.85 GF Score: 36/100

Q3 2019 Catabasis Pharmaceuticals Inc Earnings Call Transcript

Nov 07, 2019 / 01:30PM GMT
Release Date Price: $31.74 (+1.93%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Q3 2019 Catabasis Pharmaceuticals, Inc. Earnings Conference Call. (Operator Instructions)

I would now like to hand the conference over to your speaker, Andrea Matthews, Vice President of Corporate Affairs. Thank you. Please go ahead, ma'am.

Andrea L. Matthews
Catabasis Pharmaceuticals, Inc. - VP of Corporate Affairs

Thank you, Justin. Welcome to the Catabasis Pharmaceuticals conference call, where we will provide a corporate update and briefly review our third quarter 2019 financial results.

With me today are Jill Milne, Chief Executive Officer; Joanne Donovan, Chief Medical Officer; Andrew Komjathy, Chief Commercial Officer; Andrew Nichols, Chief Scientific Officer; and Noah Clauser, Vice President of Finance.

We issued a press release this morning summarizing our corporate update and our Q3 2019 financial results, which we will reference on today's call and is available on our website. I would like to note that during today's call, we will make statements related

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot